微小RNA-135b在结直肠癌发生发展及治疗中的作用研究进展  

The role of microRNA-135b in pathogenesis,development and treatment of colorectal cancer

作　　者：路丽娟 刘明浩 刘建军[1] 王瑞玲[1] Lu Lijuan, Liu Minghao, Liu Jianjun, Wang Ruiling(Department of Gastroenterology, the Second Artillery Force General Hospital of People＇s Liberation Army, Beijing 100088, Chin)

机构地区：[1]解放军第二炮兵总医院消化内科,北京100088

出　　处：《中国医药》2018年第3期477-480,共4页China Medicine

摘　　要：结直肠癌的发生是一个多基因、多步骤的过程。许多已知基因(结肠腺瘤样息肉基因、磷脂酰肌醇-3-激酶基因、肉瘤基因、P53基因等)的突变都是通过微小RNA-135b(miR-135b)起作用。miR-135b能够通过调控基因的活性,参与许多基因的转录。抑制miR-135b的表达可以同时阻断多个致癌基因的突变,有望成为不引起耐药的抗癌新途径。在血液样本及粪便中筛查miR-135b,有望成为结直肠癌早期筛查的新方法。Colorectal cancer has a muhigenic and muhistep pathogenic process. Genic mutations of adenomatous polyposis coli, phosphoinositide-3-kinases, sarcoma gene and P53 mediated by microRNA-135b participate in the pathogenesis and development of colorectal cancer. MicroRNA-135b is invo.lved in multiple signals of gene activity and transcription. Inhibition on microR-135b expression may be a novel anticancer approach. Detection of microRNA-135b in blood and fecal specimen can be a new method for early screening of colorectal cancer.

关 键 词：结直肠癌 微小RNA 微小RNA-135b 

分 类 号：R735.3[医药卫生—肿瘤]